Profound Medical(PROF)
Focus: Profound Medical is a medical device company specializing in real-time MRI-guided therapeutic systems, focused on oncology applications. The company is a publicly-traded mid-cap biotech with a narrow but innovative product focus centered on prostate cancer interventions.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
10-5 this month
Cooling — net -5 jobs in 30d
7 added, 12 removed. Slower than typical.
Should You Work at Profound Medical?
AI assessmentBest fit for early-stage medical device professionals seeking exposure to a commercializing oncology technology with meaningful cash runway but elevated execution risk.
Why Work Here
- Early-stage commercial expansion: 8 of 15 open roles are in Commercial, signaling scaled-up market entry for TULSA procedure post-regulatory approval
- Pioneering medical device technology: Real-time MRI-guided ultrasound ablation represents a differentiated, image-guided oncology platform with limited direct competition
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$11M
Key Products
TULSA Procedure
Growing
Growth
Flagship minimally-invasive platform combining real-time MRI guidance with ultrasound ablation; primary driver of commercial expansion and clinical validation efforts.
Pipeline & Clinical Trials
Help build intelligence for Profound Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.